Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
May 13, 2008
Date of Patent:
March 22, 2011
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Angelika Fretzen, Li Jing Sun, Thea Norman, G. Todd Milne
Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
Abstract: Compositions and methods for reducing the toxic effect of certain peptide toxins by administering an agent that directly or indirectly reduces disulfide bonds that are important for maintaining the toxin in an active conformation. Also described are compositions and methods for reducing the toxic effect of toxins that contain a heavy metal using an agent that destabilizes the binding of a metal ion that is important for toxin activity.
Type:
Application
Filed:
May 27, 2008
Publication date:
December 9, 2010
Applicant:
IRONWOOD PHARMACEUTICALS, INC.
Inventors:
Marco Kessler, Mark G. Currie, Robert Busby
Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Type:
Application
Filed:
September 28, 2009
Publication date:
September 16, 2010
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
February 8, 2005
Date of Patent:
August 10, 2010
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Angelika Fretzen, Li Jing Sun, Caroline Kurtz, Thea Norman, G. Todd Milne
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
December 3, 2007
Date of Patent:
June 29, 2010
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Thea Norman, G. Todd Milne
Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more sGC modulators alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
April 27, 2010
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Thea Norman, G. Todd Milne
Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
Type:
Application
Filed:
August 14, 2009
Publication date:
February 25, 2010
Applicant:
Ironwood Pharmaceuticals Inc.
Inventors:
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
Abstract: Parenteral formulations comprising ketorolac, and a compound of formula II wherein R is hydrogen or lower alkyl. Such formulations are used for the treatment and prevention of pain.
Abstract: The invention relates to compositions containing cholesterol absorption inhibitors alone or in combination with other therapeutic agents for treating non-alcoholic fatty liver disease-associated disorders by administering a therapeutically effective amount of the compositions to a subject in need thereof.
Abstract: Pharmaceutical compositions comprising certain peptides that are capable of activating the guanylate-cyclase C (GC-C) receptor are described as are the peptides and method for using the peptides and pharmaceutical compositions for treating gastrointestinal disorders and other disorder.
Abstract: The invention relates to chemical genera of organometal benzenephosphonates useful in cross-coupling organic synthesis, having general formula: where R is selected from boron, zinc, tin and silicon residues.
Type:
Application
Filed:
May 9, 2006
Publication date:
November 26, 2009
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley, JingJing Yang
Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.
Type:
Application
Filed:
June 17, 2008
Publication date:
February 26, 2009
Applicant:
IRONWOOD PHARMACEUTICALS, INC.
Inventors:
Mark G. CURRIE, John Jeffrey TALLEY, Brian CALI
Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
February 8, 2005
Date of Patent:
February 24, 2009
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun, Caroline Kurtz